<DOC>
	<DOCNO>NCT00222625</DOCNO>
	<brief_summary>Evaluation efficacy safety recombinant factor VIIa versus standard therapy prevent early haematoma growth spontaneous acute intracerebral haemorrhage patient treat oral anticoagulant antiplatelets agent</brief_summary>
	<brief_title>rFVIIa ICH Patients Treated With Anticoagulants Anti-Platelets</brief_title>
	<detailed_description>Intracerebral hemorrhage ( ICH ) deadly , disable , least treatable form stroke . Approximately 40 % patient die within 1 month ICH onset , two-thirds survivor never regain functional independence . Though guideline supportive care exist , currently treatment show randomized-controlled trial definitely improve outcome ICH . Hematoma volume critical determinant mortality functional outcome ICH , early hematoma growth may important cause early neurological deterioration . Considerable clinical interest give relationship antiplatelet antithrombotic treatment ICH . The report incidence major bleed event patient undergo antithrombotic treatment 5-11/1,000 patients/year , overall range hemorrhage 62/1,000 patients/year.In patient treat antithrombotic drug ( oral anticoagulant antiplatelets agent ) incidence rate ICH show higher general population . Moreover , mortality rate spontaneous post-traumatic event higher antithrombotic treated patient control . [ 14,15 ] rFVIIa successfully use control ICH patient hemophilia coagulation disorder , arrest intraoperative bleeding reverse coagulopathies patient undergo neurosurgical procedure . [ 19 ] rFVIIa also report prevent minimize refractory bleed non-coagulopathic patient .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>ICH patient treatment one following : ) oral anticoagulant ( INR upper 1,4 enrollment b ) aspirin , whatever dosage Male female subject , age &gt; 18 year . Informed consent INR 1.4 patient oral anticoagulant . Patients secondary ICH related infarction , tumor , cerebrovenous thrombosis , thrombolysis . Planned neurosurgical intervention . Any history haemophilia congenital acquire coagulopathy require specific antihemorrhagic treatment . Acute myocardial ischaemia acute thrombotic stroke ( within one year ) . Septicemia , intravascular disseminate coagulation . Pregnancy . Limb amputation due vascular disease claudication within last 30 day . Known suspect allergy trial product relate product . Participation trial within previous year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Intracerebral Hemorrhage</keyword>
	<keyword>Oral Anticoagulants</keyword>
	<keyword>Antiplatelet Agents</keyword>
	<keyword>Recombinant Activated Factor VII</keyword>
</DOC>